U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H14N2O2
Molecular Weight 254.2839
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LICARBAZEPINE

SMILES

NC(=O)N1C2=CC=CC=C2CC(O)C3=C1C=CC=C3

InChI

InChIKey=BMPDWHIDQYTSHX-UHFFFAOYSA-N
InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)

HIDE SMILES / InChI

Molecular Formula C15H14N2O2
Molecular Weight 254.2839
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Oxcarbazepine and its active metabolite (10,11-dihydro-10-hydroxy-carbazepine, MHD) have been effective in animal models of epilepsy that generally predict efficacy in generalized tonic-clonic seizures and partial seizures in humans. The pharmacokinetic profile of oxcarbazepine is less complicated than that of carbamazepine, with less metabolism by the cytochrome P450 system, no production of an epoxide metabolite, and lower plasma protein binding. The clinical efficacy and tolerability of oxcarbazepine have been demonstrated in trials in adults, children, and the elderly. The pharmacological activity of oxcarbazepine is primarily exerted through the 10-monohydroxy metabolite (MHD) of oxcarbazepine. The precise mechanism by which oxcarbazepine and MHD exert their antiseizure effect is unknown; however, in vitro electrophysiological studies indicate that they produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. These actions are thought to be important in the prevention of seizure spread in the intact brain. In addition, increased potassium conductance and modulation of high-voltage activated calcium channels may contribute to the anticonvulsant effects of the drug.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
TRILEPTAL

Approved Use

Oxcarbazepine tablets are indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and as monotherapy in the treatment of partial seizures in children aged 4 years and above with epilepsy, and as adjunctive therapy in children aged 2 years and above with partial seizures. Oxcarbazepine tablet is an antiepileptic drug indicated for: Adults: -Monotherapy or adjunctive therapy in the treatment of partial seizures Children: -Monotherapy in the treatment of partial seizures in children 4-16 years -Adjunctive therapy in the treatment of partial seizures in children 2-16 years (1)

Launch Date

2000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.55 μg/mL
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
7119 ng/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fasted
9349.83 ng/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fed
1630.3 ng/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fasted
3537.63 ng/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fed
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3.76 μg × h/mL
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
157372 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fasted
179002.4 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fed
173770 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fasted
197864.34 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fed
5309.5 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fasted
9445.55 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fed
5873.1 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fasted
9679.79 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fed
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.38 h
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
27%
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 1 month -4 years
n = 241
Health Status: unhealthy
Condition: partial seizures
Age Group: 1 month -4 years
Population Size: 241
Sources:
Disc. AE: Convulsions, Status epilepticus...
AEs leading to
discontinuation/dose reduction:
Convulsions (3.7%)
Status epilepticus (1.2%)
Ataxia (1.2%)
Sources:
15 g single, oral
Overdose
Dose: 15 g
Route: oral
Route: single
Dose: 15 g
Sources:
unhealthy, 13 years
n = 1
Health Status: unhealthy
Age Group: 13 years
Sex: M
Population Size: 1
Sources:
Other AEs: Vomiting...
Other AEs:
Vomiting (1 patient)
Sources:
2700 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2700 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2700 mg, 1 times / day
Sources:
unhealthy, 19-70 years
n = 71
Health Status: unhealthy
Age Group: 19-70 years
Sex: M+F
Population Size: 71
Sources:
Other AEs: Dizziness, Tremor...
Other AEs:
Dizziness
Tremor
Somnolence
Headache
Sources:
30600 mg single, oral
Overdose
Dose: 30600 mg
Route: oral
Route: single
Dose: 30600 mg
Sources:
unhealthy, 36 years
n = 1
Health Status: unhealthy
Age Group: 36 years
Sex: M
Population Size: 1
Sources:
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
n = 456
Health Status: unhealthy
Condition: partial seizures
Age Group: 4-16 years
Population Size: 456
Sources:
Disc. AE: Somnolence, Vomiting...
AEs leading to
discontinuation/dose reduction:
Somnolence (2.4%)
Vomiting (2%)
Ataxia (1.8%)
Diplopia (1.3%)
Dizziness (1.3%)
Fatigue (1.1%)
Nystagmus (1.1%)
Sources:
12 mg/kg 1 times / day steady, oral (starting)
Dose: 12 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 12 mg/kg, 1 times / day
Sources:
unhealthy, 6 years
n = 1
Health Status: unhealthy
Condition: f benign rolandic epilepsy
Age Group: 6 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Stevens Johnson syndrome...
AEs leading to
discontinuation/dose reduction:
Stevens Johnson syndrome (1 patient)
Sources:
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1524
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 1524
Sources:
Disc. AE: Hyponatremia...
AEs leading to
discontinuation/dose reduction:
Hyponatremia (2.5%)
Sources:
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Disc. AE: Dizziness, Diplopia...
AEs leading to
discontinuation/dose reduction:
Dizziness (6.4%)
Diplopia (5.9%)
Ataxia (5.2%)
Vomiting (5.1%)
Nausea (4.9%)
Somnolence (3.8%)
Headache (2.9%)
Fatigue (2.1%)
Abnormal vision (2.1%)
Tremor (1.8%)
Abnormal gait (1.7%)
Rash (1.4%)
Hyponatremia (1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Ataxia 1.2%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 1 month -4 years
n = 241
Health Status: unhealthy
Condition: partial seizures
Age Group: 1 month -4 years
Population Size: 241
Sources:
Status epilepticus 1.2%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 1 month -4 years
n = 241
Health Status: unhealthy
Condition: partial seizures
Age Group: 1 month -4 years
Population Size: 241
Sources:
Convulsions 3.7%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 1 month -4 years
n = 241
Health Status: unhealthy
Condition: partial seizures
Age Group: 1 month -4 years
Population Size: 241
Sources:
Vomiting 1 patient
15 g single, oral
Overdose
Dose: 15 g
Route: oral
Route: single
Dose: 15 g
Sources:
unhealthy, 13 years
n = 1
Health Status: unhealthy
Age Group: 13 years
Sex: M
Population Size: 1
Sources:
Dizziness
2700 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2700 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2700 mg, 1 times / day
Sources:
unhealthy, 19-70 years
n = 71
Health Status: unhealthy
Age Group: 19-70 years
Sex: M+F
Population Size: 71
Sources:
Headache
2700 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2700 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2700 mg, 1 times / day
Sources:
unhealthy, 19-70 years
n = 71
Health Status: unhealthy
Age Group: 19-70 years
Sex: M+F
Population Size: 71
Sources:
Somnolence
2700 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2700 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2700 mg, 1 times / day
Sources:
unhealthy, 19-70 years
n = 71
Health Status: unhealthy
Age Group: 19-70 years
Sex: M+F
Population Size: 71
Sources:
Tremor
2700 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2700 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2700 mg, 1 times / day
Sources:
unhealthy, 19-70 years
n = 71
Health Status: unhealthy
Age Group: 19-70 years
Sex: M+F
Population Size: 71
Sources:
Fatigue 1.1%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
n = 456
Health Status: unhealthy
Condition: partial seizures
Age Group: 4-16 years
Population Size: 456
Sources:
Nystagmus 1.1%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
n = 456
Health Status: unhealthy
Condition: partial seizures
Age Group: 4-16 years
Population Size: 456
Sources:
Diplopia 1.3%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
n = 456
Health Status: unhealthy
Condition: partial seizures
Age Group: 4-16 years
Population Size: 456
Sources:
Dizziness 1.3%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
n = 456
Health Status: unhealthy
Condition: partial seizures
Age Group: 4-16 years
Population Size: 456
Sources:
Ataxia 1.8%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
n = 456
Health Status: unhealthy
Condition: partial seizures
Age Group: 4-16 years
Population Size: 456
Sources:
Vomiting 2%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
n = 456
Health Status: unhealthy
Condition: partial seizures
Age Group: 4-16 years
Population Size: 456
Sources:
Somnolence 2.4%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
n = 456
Health Status: unhealthy
Condition: partial seizures
Age Group: 4-16 years
Population Size: 456
Sources:
Stevens Johnson syndrome 1 patient
Disc. AE
12 mg/kg 1 times / day steady, oral (starting)
Dose: 12 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 12 mg/kg, 1 times / day
Sources:
unhealthy, 6 years
n = 1
Health Status: unhealthy
Condition: f benign rolandic epilepsy
Age Group: 6 years
Sex: M
Population Size: 1
Sources:
Hyponatremia 2.5%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1524
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 1524
Sources:
Hyponatremia 1%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Rash 1.4%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Abnormal gait 1.7%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Tremor 1.8%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Abnormal vision 2.1%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Fatigue 2.1%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Headache 2.9%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Somnolence 3.8%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Nausea 4.9%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Vomiting 5.1%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Ataxia 5.2%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Diplopia 5.9%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Dizziness 6.4%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive [Activation 39.8107 uM]
likely
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [Ki 1150 uM]
no [Ki >1350 uM]
no [Ki >1350 uM]
no [Ki >1350 uM]
no [Ki >1350 uM]
no [Ki >1350 uM]
no [Ki >1350 uM]
no [Ki >1350 uM]
no [Ki >1800 uM]
no [Ki >1800 uM]
no [Ki >900 uM]
no [Ki >900 uM]
weak [Ki 270 uM]
weak [Ki 647 uM]
weak
yes [Ki 228 uM]
yes [Ki 88 uM]
yes
yes
yes
yes
yes (co-administration study)
Comment: Coadministration of OXCARBAZEPINE decreased the AUC for Felodipine and Ethinylestradiol (both CYP3A4 substrate)
Page: (Pharm) 19, (Label) 18
Drug as victim
PubMed

PubMed

TitleDatePubMed
Statins and peripheral neuropathy.
1999 Jan
Concerns with antiepileptic drug initiation: safety, tolerability, and efficacy.
2001
Oxcarbazepine: an update of its efficacy in the management of epilepsy.
2001
Behavioural effects of the new anticonvulsants.
2001
Second generation anticonvulsant medications: their use in children.
2001 Apr
[Pharmacotherapy for neuropathic pain caused by injury to the afferent nerve fibers].
2001 Apr 28
Newer antiepileptic drugs: advantages and disadvantages.
2001 Aug
The role of new antiepileptic drugs.
2001 Jul
Antiepileptic drug utilization: a Danish prescription database analysis.
2001 Jul
Advances in the treatment of epilepsy.
2001 Jul 1
Possible oxcarbazepine interaction with cyclosporine serum levels: a single case study.
2001 Mar-Apr
Monotherapy trials: presurgical studies.
2001 May
Oxcarbazepine, an antiepileptic agent.
2001 May
Rasmussen encephalitis associated with segmental vitiligo of the scalp: clinicopathologic report.
2001 May
Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels.
2001 May 15
Inhibitory effect of oxcarbazepine on high-frequency firing in peripheral nerve fibers.
2001 May 25
Pharmacologic management of epilepsy in the elderly.
2001 May-Jun
Change in oxcarbazepine (Trileptal) formulation is associated with more side effects and higher blood concentrations.
2001 Nov
Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation.
2001 Nov
Anticonvulsants in the treatment of mood disorders: assessing current and future roles.
2001 Oct
[Oxcarbazepine].
2001 Oct
Development of a high throughput 96-well plate sample preparation method for the determination of trileptal (oxcarbazepine) and its metabolites in human plasma.
2001 Oct 5
Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations.
2002
Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review of newer versus older agents.
2002
Anticonvulsants: aspects of their mechanisms of action.
2002
The 'number needed to treat' with levetiracetam (LEV): comparison with the other new antiepileptic drugs (AEDs).
2002 Apr
The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine.
2002 Apr
Women with PTSD: the psychodynamic aspects of psychopharmacologic and "hands-on" psychiatric management.
2002 Fall
Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024.
2002 Feb
Marketed new antiepileptic drugs: are they better than old-generation agents?
2002 Feb
Pediatric partial and generalized seizures.
2002 Jan
Newer therapies in the drug treatment of epilepsy.
2002 Jan
Gateways to clinical trials.
2002 Jul-Aug
Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication.
2002 Jun
Some common issues in the use of antiepileptic drugs.
2002 Mar
[New antiepileptic drugs: new therapeutic options].
2002 May
LC determination of oxcarbazepine and its active metabolite in human serum.
2002 May 15
Oxcarbazepine for mood disorders.
2002 Oct
Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI).
2002 Sep
Antiepileptic drug use during the first 12 months of vagus nerve stimulation therapy: a registry study.
2002 Sep 24
Overview of the clinical pharmacokinetics of oxcarbazepine.
2004
Drug monitoring and toxicology: a procedure for the monitoring of oxcarbazepine metabolite by HPLC-UV.
2006 Jan
Pharmacokinetics of licarbazepine in healthy volunteers: single and multiple oral doses and effect of food.
2008 May
Patents

Sample Use Guides

Bipolar I Disorder: 750- 2000 mg/day
Route of Administration: Oral
Free and bound fractions of S-licarbazepine (S-Lic) and R-licarbazepine (R-Lic) were separated by ultrafiltration after previous in vitro incubation of spiked plasma samples and protein solutions with each enantiomer at 10, 25 and 50 ug/ml.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:55:36 GMT 2023
Edited
by admin
on Fri Dec 15 15:55:36 GMT 2023
Record UNII
XFX1A5KJ3V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LICARBAZEPINE
INN   WHO-DD  
INN  
Official Name English
licarbazepine [INN]
Common Name English
10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE
Systematic Name English
Licarbazepine [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C264
Created by admin on Fri Dec 15 15:55:36 GMT 2023 , Edited by admin on Fri Dec 15 15:55:36 GMT 2023
Code System Code Type Description
INN
7788
Created by admin on Fri Dec 15 15:55:36 GMT 2023 , Edited by admin on Fri Dec 15 15:55:36 GMT 2023
PRIMARY
CAS
29331-92-8
Created by admin on Fri Dec 15 15:55:36 GMT 2023 , Edited by admin on Fri Dec 15 15:55:36 GMT 2023
PRIMARY
EPA CompTox
DTXSID50865484
Created by admin on Fri Dec 15 15:55:36 GMT 2023 , Edited by admin on Fri Dec 15 15:55:36 GMT 2023
PRIMARY
NCI_THESAURUS
C81475
Created by admin on Fri Dec 15 15:55:36 GMT 2023 , Edited by admin on Fri Dec 15 15:55:36 GMT 2023
PRIMARY
ChEMBL
CHEMBL1067
Created by admin on Fri Dec 15 15:55:36 GMT 2023 , Edited by admin on Fri Dec 15 15:55:36 GMT 2023
PRIMARY
WIKIPEDIA
Licarbazepine
Created by admin on Fri Dec 15 15:55:36 GMT 2023 , Edited by admin on Fri Dec 15 15:55:36 GMT 2023
PRIMARY
SMS_ID
100000126209
Created by admin on Fri Dec 15 15:55:36 GMT 2023 , Edited by admin on Fri Dec 15 15:55:36 GMT 2023
PRIMARY
EVMPD
SUB32907
Created by admin on Fri Dec 15 15:55:36 GMT 2023 , Edited by admin on Fri Dec 15 15:55:36 GMT 2023
PRIMARY
FDA UNII
XFX1A5KJ3V
Created by admin on Fri Dec 15 15:55:36 GMT 2023 , Edited by admin on Fri Dec 15 15:55:36 GMT 2023
PRIMARY
CHEBI
701
Created by admin on Fri Dec 15 15:55:36 GMT 2023 , Edited by admin on Fri Dec 15 15:55:36 GMT 2023
PRIMARY
PUBCHEM
114709
Created by admin on Fri Dec 15 15:55:36 GMT 2023 , Edited by admin on Fri Dec 15 15:55:36 GMT 2023
PRIMARY
Related Record Type Details
BINDER->LIGAND
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY